Hypertension is an independent risk factor for cardiovascular and cerebrovascular diseases and a major public health problem worldwide. β-blockers are one of the main drugs used clinically for hypertension treatment. A large number of clinical practices have found that there are significant individual differences in the clinical response to β-blockers among different patients, and such individual differences are closely related to polymorphisms in the cytochrome P450 2D6 (CYP2D6) and β1-adrenergic receptor (ADRB1) genes. In July 2024, the Clinical Pharmacogenomics Implementation Consortium (CPIC) issued the latest guidelines for the individualized use of β-blockers. This article reviews the recent research progress on the effects of CYP2D6 and ADRB1 gene polymorphisms on the treatment of hypertension with β-blockers, aiming to provide a theoretical basis for precision medicine in hypertension.  

Liqin Zhou, Huanjie Ma. Research Progress on CYP2D6 and ADRB1 Gene Polymorphisms in the Individualized Treatment of Hypertension with β-Blockers. Academic Journal of Medicine & Health Sciences (2026), Vol. 7, Issue 1: 46-55. https://doi.org/10.25236/AJMHS.2026.070107.

[1] Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)[J]. Lancet, 2017, 390(10112):2549-2558.  

[2] Rosengren A, Teo K, Rangarajan S, et al. Psychosocial factors and obesity in 17 high-, middle- and low-income countries: the prospective urban rural epidemiologic study[J]. Int J Obes (Lond), 2015, 39:1217–1223.  

[3] Di Palo KE, Barone NJ. Hypertension and Heart Failure: Prevention, Targets, and Treatment[J]. Cardiol Clin, 2022, 40(2):237-244.  

[4] Rysz J, Franczyk B, Rysz-Górzyńska M, et al. Pharmacogenomics of Hypertension Treatment[J]. Int J Mol Sci, 2020, 21(13):4709.  

[5] van Oort S, Beulens JWJ, van Ballegooijen AJ, et al. Association of Cardiovascular Risk Factors and Lifestyle Behaviors With Hypertension: A Mendelian Randomization Study[J]. Hypertension, 2020, 76(6):1971-1979.  

[6] Wang Y, Ye C, Kong L, et al. Independent Associations of Education, Intelligence, and Cognition With Hypertension and the Mediating Effects of Cardiometabolic Risk Factors: A Mendelian Randomization Study[J]. Hypertension, 2023, 80(1):192-203.  

[7] Thomas CD, Johnson JA. Pharmacogenetic factors affecting β-blocker metabolism and response[J]. Expert Opin Drug Metab Toxicol, 2020, 16(10):953-964.  

[8] Guidelines for Rational Use of Antihypertensive Drugs (2nd Edition)[J]. Chinese Journal of Medical Frontiers (Electronic Edition), 2017, 9(07):28-126.  

[9] Duarte JD, Thomas CD, Lee CR, Huddart R, Agundez JAG, Baye JF, Gaedigk A, Klein TE, Lanfear DE, Monte AA, Nagy M, Schwab M, Stein CM, Uppugunduri CRS, van Schaik RHN, Donnelly RS, Caudle KE, Luzum JA. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clin Pharmacol Ther. 2024 Oct;116(4):939-947.

[10] Zhao Huilin, Ding Tianlong, Wang Lirong, et al. Research Progress of PI3K/Akt Signaling Pathway in the Pathogenesis of Hypertension and Treatment with Traditional Chinese Medicine[J]. Journal of Clinical Chinese Medicine, 2024, 16(04):125-131.  

[11] Li Hairui, Peng Wei, Wu Shaorong. Application of β-Blockers in Young and Middle-Aged Hypertensive Patients[J]. Chinese General Practice, 2023, 26(02):248-254.  

[12] Fan Xiaojun. Research Status of β-Blockers in the Treatment of Cardiovascular Diseases[J]. Contemporary Medical Symposium, 2020, 18(07):135-136.  

[13] Shen Tietao. Research Progress of β-Blockers Combined with Calcium Channel Blockers in the Treatment of Hypertension[J]. China Prescription Drug, 2023, 21(07):189-192.  

[14] Taylor C, Crosby I, Yip V, et al. A Review of the Important Role of CYP2D6 in Pharmacogenomics[J]. Genes (Basel), 2020, 11(11):1295.  

[15] Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine[J]. Expert Opin Drug Metab Toxicol, 2022, 18(11):769-785.  

[16] LLerena A, Naranjo ME, Rodrigues-Soares F, et al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations[J]. Expert Opin Drug Metab Toxicol, 2014, 10(11):1569-1583.  

[17] Lei L, Wang X, Wu XD, et al. Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population[J]. Am J Transl Res, 2016, 8(8):3585-3592.  

[18] Chen K, Li Y, Yang C, et al. CYP2D6 and ADRB1 genetic polymorphisms and the selection of antihypertensive beta-receptor blockers for hypertensive patients[J]. Am J Cardiovasc Dis, 2023, 13(4):264-271.  

[19] Cronin-Fenton DP, Damkier P. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics[J]. Adv Pharmacol, 2018, 83:65-91.  

[20] He L, Chen S, Li J, et al. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese[J]. Clin Exp Pharmacol Physiol, 2020, 47(10):1659-1663.  

[21] Li S, Lin H, Sun W, et al. A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol[J]. Int J Clin Pharmacol Ther, 2017, 55(6):483-492.  

[22] Yang Q, Sun J, Li C, et al. Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS[J]. J Pharm Biomed Anal, 2019, 174:479-485.  

[23] Blake CM, Kharasch ED, Schwab M, et al. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics[J]. Clin Pharmacol Ther, 2013, 94(3):394–399.  

[24] Anstensrud AK, Molden E, Haug HJ, et al. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study[J]. Eur J Clin Pharmacol, 2020, 76(5):673-683.  

[25] Chan SW, Chu TTW, Ho CS, et al. Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients[J]. Front Med (Lausanne), 2021, 8:683498.  

[26] Mohammed Alkreathy H, Mohammed Eid Alsayyid K, Alaama JY, et al. Bisoprolol responses (PK/PD) in hypertensive patients: A cytochrome P450 (CYP) 2D6 targeted polymorphism study[J]. Saudi J Biol Sci, 2020, 27(10):2727-2732.  

[27] Guo L, Wang S, Wan Z, et al. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects[J]. J Clin Pharm Ther, 2020, 45(4):632-637.  

[28] Jung E, Ryu S, Park Z, et al. Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers[J]. J Korean Med Sci, 2018, 33(27):e182.  

[29] Hwang S, Lee S, Yoon J, et al. Population Pharmacokinetic-Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction[J]. J Korean Med Sci, 2023, 38(22):e173.  

[30] Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine[J]. Expert Opin Drug Metab Toxicol, 2022, 18(11):769-785.  

[31] Meloche M, Khazaka M, Kassem I, et al. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2020, 86(6):1015-1033.  

[32] Dou Xiaotao, Liu Tao, Zhou Qian, et al. Meta-analysis of the effect of CYP2D6 gene polymorphism on the efficacy of metoprolol[J]. Chinese Journal of Modern Applied Pharmacy, 2021, 38(01):91-99.  

[33] Poulussen FCP, Peters BJ, Hua KH, et al. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population[J]. Pharmacogenet Genomics, 2019, 29(7):179-182.  

[34] Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte--an update of guidelines[J]. Clin Pharmacol Ther, 2011, 89:662–673.  

[35] Lymperopoulos A, McCrink KA, Brill A. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol[J]. Curr Drug Metab, 2015, 17(1):30-36.  

[36] Lu S, Zhao L, Sun W, et al. Correlation analysis between ADRB1 gene polymorphism and eclampsia[J]. Panminerva Med, 2023, 65(2):277-278.  

[37] Muslimova E, Rebrova T, Kondratieva D, et al. Expression of the β1-adrenergic receptor (ADRB1) gene in the myocardium and β-adrenergic reactivity of the body in patients with a history of myocardial infarction[J]. Gene, 2022, 844:146820.  

[38] Guerra LA, Lteif C, Arwood MJ, et al. Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers[J]. Pharmacogenomics J, 2022, 22(1):62-68.  

[39] Xie HG, Dishy V, Sofowora G, et al. Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo[J]. Pharmacogenetics, 2001, 11(3):191-197.  

[40] Thomas CD, Johnson JA. Pharmacogenetic factors affecting β-blocker metabolism and response[J]. Expert Opin Drug Metab Toxicol, 2020, 16(10):953-964.  

[41] Wu D, Li G, Deng M, et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension[J]. J Int Med Res, 2015, 43(3):424-434.  

[42] Dou Xiaotao, Liu Tao, Wang Haoyu, et al. Meta-analysis of the effect of ADRB1 389 locus gene polymorphism on the efficacy of metoprolol[J]. Modern Medicine and Health, 2020, 36(21):3414-3419.  

[43] Shen Juanqin, Wang Lin, Xu Shaokun, et al. Impact of ADRB1 gene polymorphism on the efficacy of metoprolol sustained-release tablets in hypertensive patients[J]. Journal of Electrocardiology and Circulation, 2023, 42(02):145-148.  

[44] Chen L, Xiao T, Chen L, et al. The association of ADRB1 and CYP2D6 polymorphisms with antihypertensive effects and analysis of their contribution to hypertension risk[J]. Am J Med Sci, 2018, 355:235–239.  

[45] Petersen M, Andersen JT, Jimenez-Solem E, et al. Effect of the Arg389Gly β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment[J]. Clin Exp Pharmacol Physiol, 2012, 39(9):779-785.  

[46] Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, et al. Pharmacogenetic polymorphisms affecting bisoprolol response[J]. Biomed Pharmacother, 2021, 142:112069.  

[47] Zhang Tianqi, Li Ting, Zhang Tian, et al. Meta-analysis of the impact of ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol[J]. China Pharmacy, 2024, 35(05):601-606.  

[48] Zeng W, Chu TTW, Ho CS, et al. Lack of Effects of Renin-Angiotensin-Aldosterone System Activity and Beta-Adrenoceptor Pathway Polymorphisms on the Response to Bisoprolol in Hypertension[J]. Front Cardiovasc Med, 2022, 9:842875.  

[49] Si D, Wang J, Xu Y, et al. Association of common polymorphisms in beta1-adrenergic receptor with antihypertensive response to carvedilol[J]. J Cardiovasc Pharmacol, 2014, 64:306–309.  

[50] Sehrt D, Meineke I, Tzvetkov M, et al. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics[J]. Pharmacogenomics, 2011, 12(6):783-795.